Miromatrix Medical Inc.
This article was originally published in Start Up
Executive Summary
Regenerative medicine start-up Miromatrix Medical is working to commercialize a technology known as perfusion decellularization. Its proprietary, patent-protected technology involves the decellularization of any vascularized tissue, up to and including whole organs, leaving behind a completely preserved native scaffold (matrix) that retains the original architecture, mechanical properties and vascular network of the tissue or organ. This scaffold can then be repopulated with vascular- and organ-specific regenerative cells and, under controlled conditions in a bioreactor, a biocompatible, functioning organ or tissue is created.
You may also be interested in...
Start-Up Previews (10/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Eyeing New Drugs For Glaucoma," features profiles of Altheos, Amakem and Mimetogen Pharmaceuticals. Plus these Start-Ups Across Health Care: Aragon Surgical, Arcarios, Carolina BioPharm, Miromatrix Medical and Pathogenica.
Floelle Inc.
Floelle Inc. is developing a nonsurgical solution for women with stress and mixed urinary incontinence that it thinks will address the drawbacks of current technologies and provide a safe and effective solution that is convenient for patients. The Floelle device resides in the urethra where it allows normal urination, but a pressure-sensitive valve blocks the involuntary urine leaks caused by coughing, laughing, sneezing, and other activities that increase intra-abdominal pressure in women with stress urinary incontinence.